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Abstract 
Mycobacterium tuberculosis (MTB) remains one of the most significant human pathogens since 
its discovery in 1882. An estimated 1.5 million people died from tubercle bacillus (TB) in 2006, 
and globally, there were an estimated 9.27 million incident cases of TB in 2007. Glyoxylate 
bypass pathway occurs in a wide range of pathogens and plays a key role in the pathogenesis 
of Mycobacterium tuberculosis. Isocitrate lyase (ICL) can catalyses the first step of this pathway, 
and reversibly cleaves isocitrate into succinate and glyoxylate. So, ICL may represent a good 
drug target for the treatment of tuberculosis. ICL was cloned, expressed, and purified, and a 
high-throughput screen (HTS) developed to screen active molecule from a mannich base 
compounds library for inhibition of ICL. This assay had signal to noise (S/N) of 650.6990 and 
Z’ factor of 0.8141, indicating that the assay was suitable for HTS. Screening of a collection of 
124 mannich base compounds resulted in the identification of one mannich base compound, 
which has a significant inhibitory activity. So, a new family of compound was first reported to 
inhibit the activity of Mycobacterium tuberculosis ICL. This family of compound might offer new 
avenue to explore better anti-tuberculosis and fungi drugs. 
Key words: Isocitrate Lyase, Mycobacterium tuberculosis, Drug Target, High-Throughput Screening, 
mannich bases. 
Introduction 
Isocitrate  lyase  (ICL;  EC  4.1.3.1)  catalyses  the 
first  step  of  the  glyoxylate  bypass  pathway,  which 
reversibly catalysis isocitrate into succinate and gly-
oxylate. It is the key enzyme in the glyoxylate bypass 
pathway  [1].  Glyoxylate  shunt  was  reported  to  be 
pivotal for microbes to survive and thrive on the fatty 
acid and two-carbon compound as sole carbon source 
[2]. 
ICL  existed  extensively  in  organisms  such  as 
bacteria, nematodes, fungi and plants [3]. No human 
being  homologs  have  been  documented  [3].  This 
made ICL a promising target for broad spectrum an-
tibiotics. ICL is essential for Mycobacterium tuberculosis 
growth in activated macrophages and persistence in 
macrophages and mice [4], and  virulence factors  of 
Candida albicans, Rhodococcus equi [5-7].  
ICL was intensively pursued as drug target to 
combat  tuberculosis.  Tuberculosis  was  once  held  at 
bay by the introduction of antibiotics and there was a 
widespread optimism that it is just a matter of time to 
eradicate  them.  However,  several  factors,  including 
the  emergence  of  drug  resistance,  multi-drug  re-
sistance  and  even  extensive  resistance,  co-infection 
with HIV and poor compliance of patients largely due 
to  the  lengthy  treatment  regimen,  result  in  the 
re-establishment of tuberculosis as a major scourge of Int. J. Biol. Sci. 2011, 7 
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public  health.  And  this  once  optimism  was  relent-
lessly  pulverized.  Intense  investigations  on  ICL  in-
hibitor have revealed variety of drug leads promising 
to  proceed  into  next  stage[8].  Many  have  put  on  a 
premium  on  ICL  as  a  priority  target,such  as  WHO 
(World Health Organization) [9], GSK and Rockefeller 
University[10].  ICL  expression  was  reported  to  be 
highly  spatiotemporal  and  conventionalscreening 
might miss some promising leads [11].  
Β-amino  ketones  are  the  key  intermediates  for 
the synthesis of lots of drugs and natural products, 
and are also important bioactive substances [12], with 
function  of  anti-inflammatory  [13,  14],  anti-cancer 
[15-18],  anti-bacterial  [18,  19],  anti-virus,  sedation, 
analgesia,  hypotension,  edema  suppression  and  an-
ti-coagulation. more diverse activities were reported, 
such as: anti-androgen[20], insulin sensitizer, excited 
peroxisome proliferator-activated receptors (PPARs), 
inhibit cholesterol acyltransferase (ACAT), and pro-
mote  high-density  lipoprotein  receptor  (SRBI)  ex-
pression  and  reverse  tumor  multi-drug  resistance, 
such as pharmacological activity, can be used as the 
prevention and treatment of insulin resistance-related 
diseases, diabetes, obesity, atherosclerosis, fatty liver, 
hyperlipidemia,  inflammation,  tumor  diseases,  such 
as multi-drug resistance of the drug/precursor mate-
rial  [21-24].  Our  working  hypothesis  is  these  com-
pounds might be active against ICL. 
A previously proved high-throughput screening 
model for ICL inhibitors in our lab [25] was employed 
to screen new ICL inhibitors from the mannich base 
compounds  library.  Compound  Ydcm67  (Fig.1) 
demonstrated a strong inhibitory activity to ICL. 
 
 
Fig.1 Structure of compound Ydcm67 
 
MATERIALS AND METHODS 
Materials 
Mycobacterium tuberculosis H37Rv was purchased 
from Chongqing Pulmonary Hospital, China; Esche-
richia  coli  DH5α,  E.  coli  DE3  (BL21)  and  plasmid 
pET-28a  (+)  were  employed;  Pfu  DNA  Polymerase, 
DNA marker were purchased from Tiangen Biotech 
(Beijing) Co.,Ltd; DNA purification kit was purchased 
from SBS Genetech Co., Ltd; BamHI, HindIII, T4 DNA 
ligase,  and  dNTP  were  purchased  from  Takara; 
Ni-Sepharose and ȀKTA prime were from Amersham 
Biosciences.  Isocitrate  and  itaconic  anhydrate  were 
obtained  from  Sigma-Aldrich.  The  mannich  base 
compounds library was constructed by Pro. Dacheng 
Yang’s lab, School of Chemistry and Chemical Engi-
neering,  Southwest  University,  China.  The  96-well 
plate for UV assay was purchased from Greiner. Ab-
sorbance  was  read  at  324nm  on  SpectraMaxs  190 
(Molecular Devices, Sunnyvale, CA). 
Cloning and Expression of Recombinant ICL 
The  genomic  DNA  was  prepared  using 
CTAB[26].  A  1.3-kb  DNA  fragment  containing  the 
aceA  gene  was  amplified  by  nested  PCR  using  the 
following four oligonucleotide primers: OutF: 5’ CGC 
CTC GCT GTT GAA TCT GT 3’ and OutR: 5’ CGC 
TCA  CTG  TTC  CTC  CTC  AAA  T  3’  for  first  PCR; 
ICLF: 5’ TA GGA TCC ATG TCT GTC GTC GGC AC 
3’ and ICLR: 5’ TCA AAG CTT CTA GTG GAA CTG 
GCC  CTC  T  3’  (restriction  sites  are  indicated  with 
single  underlines)  for  second  PCR.  The  amplified 
DNA  was  digested  using  BamHI  and  HindIII,  and 
ligated into pET-28a (+), then the recombinant plas-
mid pET28a-ICL was transformed into E. coli DH5α. 
The  nucleotide  sequence  was  done  on  an  ABI  3730 
sequencer.  For  over-expression,  E.  coli  DE3  (BL21) 
carrying  the  recombinant  plasmid  pET28a-ICL  was 
grown  to  an  exponential  phase  at  37℃  in  Lu-
ria-Bertani (LB) medium [27] plus kanamycin (50 μg 
ml-1). Expression of ICL was induced by 0.1mM IPTG 
for 4h at 30℃. Cells were harvested by centrifugation 
at 4℃, and cell pellets were stored at -20℃. 
Purification of ICL 
Using Buffer A (50mM NaH2PO4, 300mM NaCl, 
10mM imidazole, pH 8.0) as the lysis buffer, and the 
lysate was centrifuged at 13,000 g for 30 min at 4℃. 
The cell extract was applied to Ni-sepharose (Amer-
sham  Biosciences)  and  fractions  with  ICL  activity 
were collected and stored at 4℃ for 2 months with no 
loss of activity. 
Enzyme Assay 
Isocitrate lyase activity was determined at 37℃ 
by  measuring  the  formation  of  glyox-
ylate-phenylhydrazone in the presence of phenylhy-
drazine  and  isocitrate  lyase  at  324nm  based  on  the 
method described [28]. The reaction buffer include 50 
mM potassium phosphate, 4 mM MgCl2, 4 mM Phe-
nylhydrazine HCl, 12 mM Cysteine HCl, pH 7.0, and 
it was kept on ice until use. The mixture of 188 μl re-
action buffer and 2 μl recombinant ICL solution was 
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incubated at 37℃ for 30 min, and the change of ab-
sorbance at 324nm was measured after the addition of 
10 μl isocitrate. The Km and Vmax was gained using 
the Hanes-Woolf plot [29], with the slope = 1/Vmax 
and the intercept on the x axis = -Km.  
Optimization of Enzyme Assay in 96-Well Plate 
The mixture of reaction buffer and different unit 
enzyme  was  incubated  at  37℃  for  30  min,  and  ab-
sorbance at 324nm was read as control values. Then 
isocitrate was added, and the plate was incubated at 
37℃. The absorbance at 324nm was read as experi-
mental values every 10 min for 5 times. 
Preparation of Mannich Base Solution 
The mannich base compounds were dissolved in 
DMSO to obtain final concentrations  of 1.0 mg/ml, 
and stored at -20℃. 
High-Throughput Screening 
The test mannich base solutions were diluted on 
the mother plate (1.0 mg/ml in 100% DMSO), and 10 
μl of each extract solution was added into each well 
(equivalent to a final concentration of 0.05 mg/ml) of 
a  96-well  plate.  The  A1,  B1,  and  C1  represent  the 
background,  negative  control  and  positive  control 
(0.05 M oxalic acid) respectively. Subsequently, 178 μl 
reaction buffer, 10 μl compound solution, 2 μl recom-
binant protein ICL solution, and 10 μl isocitrate solu-
tion  (0.04  M)  was  added  to  each  well,  and  the  ab-
sorbance was measured as described above. The in-
hibition >50% of extracts were picked up for the fol-
lowing  screen  to  reconfirm  the  inhibition,  and  the 
screen assay was done in duplicate. To determine the 
IC50, five concentrations were used. 
Data Analysis 
The activity detection of ICL was based on the 
absorbance at 324 nm, and the activity was calculated 
by  the  change  of  absorbance  (experimental  values 
control  values).  The  signal  to  noise  (S/N)  and 
screening window coefficients (Z’ factor) were calcu-
lated as described by Zhang, et al[30] to evaluate the 
suitability of the model for screening. Data that were 
detected from eight wells have been used to calculate 
the S/N and Z’ factor. 
RESULTS 
Screening and Identification of Recombinant 
Plasmid 
Recombinant plasmid was isolated from clones 
growing on LB medium supplement with kanamycin 
(50 μg ml-1), and found to contain an intact copy of the 
1.3-kb  DNA  by  two  enzymes  digestion  (Fig.2).  The 
sequence result showed that no mutations were dis-
covered, confirming the construction of recombinant 
plasmid pET28a-ICL. 
 
 
Fig.2 Using restriction enzymes digest recombinant plas-
mid pET28a-ICL. Lane 1: Marker IV; Lane 2 and 4: BamHI 
and  HindIII  single  digestion;  Lane  3:  BamHI  and  HindIII 
double digestion.  
 
Overexpression of Recombinant ICL 
Recombinant  ICL  was  overexpressed  in  E. coli 
DE3  (BL21).  Using  SDS-PAGE  analysis  of  recombi-
nant  ICL  in  the  inclusion  body  and  supernatant 
(Fig.3A).  Than  using  ÄKTA  prime  (Amersham  Bio-
sciences,  USA)  purified  recombinant  ICL  protein 
(Fig.3B). 
 
 
Fig.3  A: SDS-PAGE  analysis of recombinant ICL  in the 
inclusion body and supernatant. Lane 1: Protein marker; 
Lane 2-3: Precipitate and supernatant of sonicated broken 
E.coli DE3 (BL21) transformed with pET28a-ICL, respec-
tively. B: SDS-PAGE analysis of recombinant ICL that puri-
fied. Lane 1: Protein marker; Lane 2: Purified protein. Int. J. Biol. Sci. 2011, 7 
 
http://www.biolsci.org 
379 
Enzyme Assay and Optimization 
The  recombinant  enzyme  activity  was  21,500 
U/L. Using the Hanes-Woolf plot, the Km and Vmax 
were  determined  to  be  219  mM  and  3.127 
mM/min/mg, respectively. The results showed that 
the  production  of  glyoxylate-phenylhydrazone  was 
linear with the time of incubation up to 20 min (Fig.4) 
and with the amount of protein in the assay at 2mM 
concentration of isocitrate. Therefore, the  optimized 
condition of ICL for assay was fixed at 2μl enzyme 
solution  (approximately  equal  to  215  U/L)  in  each 
well, and an incubation time of 20 min at 37℃ was 
used. 
The IC50 value of oxalic acid to ICL was 0.013 M 
determined over a range of inhibitors’ final concen-
trations (0.005 M - 0.05 M) under the optimized con-
ditions (Fig.5). 
 
 
 
Fig.4 Isocitrate lyase activity as determined by the assay as a function of time. 
 
 
 
Fig.5 Dose response curves for oxalic acid which inhibits ICL activity 
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As described in Materials and Methods, the sig-
nal to noise (S/N) and Z’ factor was calculated from 
the control wells of screening plates to determine the 
suitability of the assay for high throughput screening. 
The Z’ factor reflects the dynamic range as well as the 
variation of the assay and is a useful tool for assay 
comparisons  and  assay  quality  determinations[30]. 
The assay exhibits S/N of 650.6990 and Z’ factor of 
0.8141 (Table 1). 
Table 1. ICL activity assay parameters 
  Value 
M Signal a  1.0211 
M Background b  0.0088 
SD Background c  0.0016 
Signal-to-noise(S/N) d  650.6990 
Z` factor e  0.8141 
a: M Signal, mean of signal  
b: M Background, mean of background 
c: SD Background, standard deviation of the background 
d and e[30]: the S/N and Z` factor were calculated by the equations: 
(M Signal-M Background)/SD Background; 1-[(3×SD Positive Control) + (3×SD Nega-
tive Control)/(mean positive control-mean negative control)], respec-
tively. 
 
 
High-Throughput Screening 
In this assay, 124 mannich base compounds were 
tested. All compounds were evaluated in the assay at 
a  final  concentration  of  0.05  mg/ml.  Inhibition  of 
more  than  50%  was  defined  as  a  hit.  We  found 
Ydcm67 has a significant inhibitory activity (Table 2). 
Table 2. Potency of oxalic acid and Ydcm67 against My-
cobacterium tuberculosis ICL activity using the colorimetric 
assay 
  OD324 
M Background a  0.0088 
M Negative Control b  1.0211 
M Positive Control c  0.0538 
M Sample d  0.4400 
IR Positive Control e  95.55% 
IR Sample f  57.40% 
a: M Background, mean of background 
b: M Negative Control, no inhibitor 
c: M Positive Control, mean of positive control, using 0.05M oxalic acid 
solution as positive control 
d: M Sample , mean of sample, using 0.05 mg/ml Ydcm67 solution 
e: IR Positive Control, percent inhibition of oxalic acid: (M Negative Control - M 
Positive Control)/( M Negative Control - M Background) * 100% 
f: IR Sample, percent inhibition of Ydcm67: (M Negative Control - M Sample)/( 
M Negative Control - M Background) * 100% 
 
 
 
The  IC50  value  of  Ydcm67  to  ICL  was  0.0535 
mg/ml determined  over a range of inhibitors’ final 
concentrations  (0.0063  mg/ml  -  0.05  mg/ml)  under 
the optimized conditions (Fig.6). 
 
 
 
 
Fig.6 Dose response curves for Ydcm67 which inhibits ICL activity 
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DISCUSSION 
To accommodate the assay described to HTS, the 
optimization of the assay was performed. The incu-
bation time was changed to 30 min to make full in-
teraction  between  enzyme  and  inhibitors,  and  the 
changeable values of the absorbance at 324nm in 20 
min  was  used  to  represent  the  activity  of  the  ICL. 
Additionally,  2  mM  isocitrate  and  0.043U  ICL  at  a 
final concentration were used in the assay. 124 man-
nich  bases  were  screened  in  this  assay,  and  one  of 
them, Ydcm67, exhibited the inhibition of ICL activity, 
the IC50 value of Ydcm67 to ICL was 0.0535 mg/ml, 
and resulting in a total hit rate of 0.81%. Typically, Z’ 
factor >0.5 and S/N >10 are considered favorable for 
high throughput screening. Our assay exhibiting S/N 
of 650.6990 and Z’ factor of 0.8141 and the reproduci-
bility of positive compounds indicates that it is suita-
ble for high-throughput screening. 
Simulated 3D structure of Ycdm67 (Fig.7A) gen-
erated via ChemSketch demonstrates that this mole-
cule might function by wedging in the active site of 
ICL (Fig.7B).  
This  is  the  first  report  that  a  high-throughput 
screening assay was developed to screen the mannich 
base, and one hit is active against ICL. However, in 
vivo data are needed to evaluate the compound’s ef-
ficacy and provide structure-activity relationship in-
formation. 
 
 
Fig.7 A: The 3D structure of Ydcm67 (White: H; Lightcyan: C; Red: O; Mazarine: N; Green:Cl). B: The crystal structure of 
isocitrate lyase from Mycobacterium tuberculosis (http://www.rcsb.org/pdb/explore/images.do?structureId=1F8I). 
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